NASDAQ:VIR Vir Biotechnology (VIR) Stock Forecast, Price & News $9.21 -0.05 (-0.54%) (As of 09/28/2023 ET) Add Compare Share Share Today's Range$9.10▼$9.3050-Day Range$9.14▼$14.3552-Week Range$8.90▼$31.55Volume1.12 million shsAverage Volume1.15 million shsMarket Capitalization$1.24 billionP/E RatioN/ADividend YieldN/APrice Target$37.11 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Vir Biotechnology MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside302.9% Upside$37.11 Price TargetShort InterestBearish5.82% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.50Based on 6 Articles This WeekInsider TradingSelling Shares$637,408 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($4.66) to ($4.72) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.47 out of 5 starsMedical Sector186th out of 969 stocksBiological Products, Except Diagnostic Industry25th out of 161 stocks 4.4 Analyst's Opinion Consensus RatingVir Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $37.11, Vir Biotechnology has a forecasted upside of 302.9% from its current price of $9.21.Amount of Analyst CoverageVir Biotechnology has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.82% of the float of Vir Biotechnology has been sold short.Short Interest Ratio / Days to CoverVir Biotechnology has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vir Biotechnology has recently increased by 11.16%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVir Biotechnology does not currently pay a dividend.Dividend GrowthVir Biotechnology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VIR. Previous Next 2.5 News and Social Media Coverage News SentimentVir Biotechnology has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Vir Biotechnology this week, compared to 5 articles on an average week.Search InterestOnly 6 people have searched for VIR on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows5 people have added Vir Biotechnology to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vir Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $637,408.00 in company stock.Percentage Held by Insiders18.10% of the stock of Vir Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.05% of the stock of Vir Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Vir Biotechnology are expected to decrease in the coming year, from ($4.66) to ($4.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vir Biotechnology is -4.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vir Biotechnology is -4.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVir Biotechnology has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Vir Biotechnology (NASDAQ:VIR) StockVir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California.Read More VIR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VIR Stock News HeadlinesSeptember 27, 2023 | msn.comHIV vaccine starts trials in USA, South AfricaSeptember 26, 2023 | msn.comMedical breakthrough HIV vaccine starts trials in USA, South AfricaSeptember 28, 2023 | The Oxford Club (Ad)Better Than Oil Stocks?The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. September 26, 2023 | msn.comNovel HIV vaccine begins trial after decades of researchSeptember 22, 2023 | americanbankingnews.comVir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by BrokeragesSeptember 20, 2023 | msn.comClinical trials of HIV vaccine to start in the USSeptember 20, 2023 | finance.yahoo.comVir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIVSeptember 8, 2023 | msn.comVir stock hits new 52-week low in wake of BofA downgradeSeptember 28, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.September 8, 2023 | markets.businessinsider.comInfectious Disease Player Vir Biotech Has Limited Near Term Upside, Analyst DowngradesAugust 29, 2023 | finance.yahoo.comVir Biotechnology to Participate in Upcoming Investor Healthcare ConferencesAugust 21, 2023 | seekingalpha.comVir Biotechnology: Strong Balance Sheet But Commercial Prospects Await Further ClarityAugust 18, 2023 | markets.businessinsider.comAkero Therapeutics (AKRO) Gets a Buy from J.P. MorganAugust 10, 2023 | seekingalpha.comVir Biotechnology, Inc. 2023 Q2 - Results - Earnings Call PresentationAugust 7, 2023 | markets.businessinsider.comVir Biotechnology (VIR) Receives a Buy from H.C. WainwrightAugust 7, 2023 | msn.comHC Wainwright & Co. Maintains Vir Biotechnology (VIR) Buy RecommendationAugust 7, 2023 | finance.yahoo.comAnalysts Just Made A Major Revision To Their Vir Biotechnology, Inc. (NASDAQ:VIR) Revenue ForecastsAugust 4, 2023 | finance.yahoo.comVir Biotechnology, Inc. (NASDAQ:VIR) Q2 2023 Earnings Call TranscriptAugust 3, 2023 | finance.yahoo.comVir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial ResultsJuly 26, 2023 | finance.yahoo.comVir Biotechnology to Provide Business Update and Report Second Quarter 2023 Financial Results on August 3, 2023July 22, 2023 | msn.comVir Biotechnology’s stock slides 40% after it says mid-stage trial of a flu treatment failed to meet main goalsJuly 22, 2023 | msn.comGoldman Sachs Maintains Vir Biotechnology (VIR) Buy RecommendationJuly 22, 2023 | msn.comBarclays Maintains Vir Biotechnology (VIR) Overweight RecommendationJuly 21, 2023 | finance.yahoo.comBiotech Stock Roundup: BBIO, ARGX Soar on Study Results, APLS Down on Safety IssuesJuly 21, 2023 | seekingalpha.comVir Biotechnology Sneezes On Flu Data, But May Be Worth HoldingJuly 21, 2023 | reuters.comVir Biotech slumps to over 3-year low as flu prevention therapy fails trialJuly 21, 2023 | msn.comVir Biotech plunges as mid-stage study for flu candidate failsSee More Headlines Receive VIR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vir Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address VIR Company Calendar Last Earnings8/03/2023Today9/28/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VIR CUSIPN/A CIK1706431 Webwww.vir.bio Phone415-906-4324FaxN/AEmployees576Year FoundedN/APrice Target and Rating Average Stock Price Forecast$37.11 High Stock Price Forecast$95.00 Low Stock Price Forecast$14.00 Forecasted Upside/Downside+305.1%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$515.84 million Net Margins-53.38% Pretax Margin-55.98% Return on Equity-13.08% Return on Assets-10.07% Debt Debt-to-Equity RatioN/A Current Ratio8.63 Quick Ratio8.63 Sales & Book Value Annual Sales$1.62 billion Price / Sales0.76 Cash Flow$3.82 per share Price / Cash Flow2.40 Book Value$15.61 per share Price / Book0.59Miscellaneous Outstanding Shares134,250,000Free Float109,952,000Market Cap$1.23 billion OptionableOptionable Beta0.16 The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMs. Johanna Friedl-Naderer (Age 55)Exec. VP & COO Comp: $1.92MDr. Ann M. Hanly Ph.D. (Age 53)Exec. VP & Chief Technology Officer Comp: $842.23kDr. Phillip Pang M.D. (Age 48)Ph.D., Exec. VP, Chief Medical Officer & Interim Head of Research Comp: $837.38kDr. Marianne De Backer M.B.A. (Age 54)M.Sc., Ph.D., CEO & Director Dr. Klaus Frueh Ph.D. (Age 63)Co-Founder & Scientific Advisor Dr. Lawrence Corey M.D. (Age 76)Co-Founder & Scientific Advisor Dr. Louis J. Picker M.D.Co-Founder & Scientific AdvisorMr. Sung H. Lee (Age 53)Exec. VP & CFO Ms. Heather Rowe ArmstrongVP of Investor RelationsMs. Vanina De Verneuil J.D.Sr. VP of Legal & Corp. Sec.More ExecutivesKey CompetitorsTwist BioscienceNASDAQ:TWSTIovance BiotherapeuticsNASDAQ:IOVABioCryst PharmaceuticalsNASDAQ:BCRXApogee TherapeuticsNASDAQ:APGEPrime MedicineNYSE:PRMEView All CompetitorsInsiders & InstitutionsBarclays PLCSold 48,975 shares on 9/21/2023Ownership: 0.137%Perceptive Advisors LLCBought 1,816,070 shares on 8/24/2023Ownership: 1.459%Alberta Investment Management CorpBought 11,954 shares on 8/24/2023Ownership: 0.017%Virginia Retirement Systems ET ALBought 39,900 shares on 8/22/2023Ownership: 0.030%Teachers Retirement System of The State of KentuckyBought 1,328 shares on 8/21/2023Ownership: 0.018%View All Insider TransactionsView All Institutional Transactions VIR Stock - Frequently Asked Questions Should I buy or sell Vir Biotechnology stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vir Biotechnology in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" VIR shares. View VIR analyst ratings or view top-rated stocks. What is Vir Biotechnology's stock price forecast for 2023? 8 Wall Street research analysts have issued 12-month price targets for Vir Biotechnology's shares. Their VIR share price forecasts range from $14.00 to $95.00. On average, they expect the company's share price to reach $37.11 in the next twelve months. This suggests a possible upside of 305.1% from the stock's current price. View analysts price targets for VIR or view top-rated stocks among Wall Street analysts. How have VIR shares performed in 2023? Vir Biotechnology's stock was trading at $25.31 at the beginning of the year. Since then, VIR stock has decreased by 63.8% and is now trading at $9.16. View the best growth stocks for 2023 here. When is Vir Biotechnology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our VIR earnings forecast. How were Vir Biotechnology's earnings last quarter? Vir Biotechnology, Inc. (NASDAQ:VIR) issued its earnings results on Thursday, August, 3rd. The company reported ($1.45) EPS for the quarter, missing the consensus estimate of ($1.21) by $0.24. The company had revenue of $3.80 million for the quarter, compared to the consensus estimate of $22.39 million. Vir Biotechnology had a negative net margin of 53.38% and a negative trailing twelve-month return on equity of 13.08%. The business's revenue was up 379999900.0% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.58) EPS. What ETFs hold Vir Biotechnology's stock? ETFs with the largest weight of Vir Biotechnology (NASDAQ:VIR) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), ETFMG Treatments Testing and Advancements ETF (GERM), ALPS Medical Breakthroughs ETF (SBIO), Invesco S&P SmallCap Health Care ETF (PSCH), Invesco S&P SmallCap 600 Pure Growth ETF (RZG), Hartford Multifactor Small Cap ETF (ROSC) and First Trust Nasdaq Pharmaceuticals ETF (FTXH).SPDR S&P 600 Small Cap ETF (SLY). What is George Scangos' approval rating as Vir Biotechnology's CEO? 7 employees have rated Vir Biotechnology Chief Executive Officer George Scangos on Glassdoor.com. George Scangos has an approval rating of 85% among the company's employees. When did Vir Biotechnology IPO? (VIR) raised $149 million in an initial public offering on Friday, October 11th 2019. The company issued 7,100,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Barclays served as the underwriters for the IPO. What is Vir Biotechnology's stock symbol? Vir Biotechnology trades on the NASDAQ under the ticker symbol "VIR." Who are Vir Biotechnology's major shareholders? Vir Biotechnology's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Bank Julius Baer & Co. Ltd Zurich (23.88%), SB Investment Advisers UK Ltd. (12.43%), BlackRock Inc. (10.41%), State Street Corp (4.04%), Temasek Holdings Private Ltd (3.82%) and Baillie Gifford & Co. (2.97%). Insiders that own company stock include Ann M Hanly, Charles Elliott Sigal, Endurance (Cayman) Ltd Svf, George A Scangos, Herbert Virgin, Howard Horn, Janet Napolitano, Jay Parrish, Johanna Friedl-Naderer, Medpace Investors, Llc, Phillip Pang, Robert J More, Robert J More, Saira Ramasastry, Steven J Rice, Vicki L Sato and Vicki L Sato. View institutional ownership trends. How do I buy shares of Vir Biotechnology? Shares of VIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Vir Biotechnology's stock price today? One share of VIR stock can currently be purchased for approximately $9.16. How much money does Vir Biotechnology make? Vir Biotechnology (NASDAQ:VIR) has a market capitalization of $1.23 billion and generates $1.62 billion in revenue each year. The company earns $515.84 million in net income (profit) each year or ($1.97) on an earnings per share basis. How many employees does Vir Biotechnology have? The company employs 576 workers across the globe. How can I contact Vir Biotechnology? Vir Biotechnology's mailing address is 499 ILLINOIS STREET SUITE 500, SAN FRANCISCO CA, 94158. The official website for the company is www.vir.bio. The company can be reached via phone at 415-906-4324 or via email at ir@vir.bio. This page (NASDAQ:VIR) was last updated on 9/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vir Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.